Opportunity knocks thrice for the iconic growth investor.

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

If you are trying to work out whether CRISPR Therapeutics is attractively priced or not, starting with the recent share ...

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

It crushed analyst estimates on both the top and bottom lines. This, despite significant erosion in both metrics. For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That ...